On 12 Nov 2026 Fortive closed at $67.85, +23.3% this year; market cap $20.62bn, P/E 31.6.
Industrials · Industrial Machinery & Supplies & Components · NYSE · United States
Fortive Corporation designs, develops, manufactures, and markets products, software, and services in the United States, China, and internationally. It operates through Intelligent Operating Solutions and Advanced Healthcare Solutions segments. The Intelligent Operating Solutions segment provides advanced instrumentation, software, and services, including maintenance, repair, measurement and condition monitoring, facility and asset lifecycle software applications, and connected worker safety and compliance solutions for manufacturing, process industries, healthcare, utilities and power, communications and electronics, and other industries. This segment markets its products and services under the ACCRUENT, FLUKE, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, and SERVICECHANNEL brand names. The Advanced Healthcare Solutions segment provides critical workflow solutions comprising instrument sterilization, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions under the ASP, CENSIS, FLUKE BIOMEDICAL, LANDAUER, and PROVATION brand names. Fortive Corporation was incorporated in 2015 and is headquartered in Everett, Washington.
| Market cap | $20.62bn |
| P/E (trailing) | 31.6 |
| EPS (TTM) | $2.15 |
| Beta | 0.94 |
| Dividend | $0.28 |
| Dividend yield | 0.41% |
| Ex-dividend date | 27 Nov 2026 |
| Latest report | 28 Oct 2026 |
| Next earnings | 26 Jan 2027 |
| YTD | +23.3% |
| 1Y | +31.0% |
| 3Y | +11.8% |
| 5Y | +3.3% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $5.14bn | $579.20m | $978.10m |
| 2024 | $6.23bn | $832.90m | $1.41bn |
| 2023 | $6.07bn | $865.80m | $1.25bn |
| 2022 | $5.83bn | $755.20m | $1.21bn |
| 2021 | $5.25bn | $608.40m | $911.10m |
We publish no single base value for Fortive. Our valuation methods put it between $12.71 and $15.65 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.